PubMed:31445345 JSONTXT

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":169,"end":181},"obj":"CI"},{"id":"T2","span":{"begin":433,"end":445},"obj":"CI"},{"id":"T3","span":{"begin":671,"end":683},"obj":"CI"},{"id":"T4","span":{"begin":829,"end":841},"obj":"CI"},{"id":"T5","span":{"begin":861,"end":873},"obj":"CI"},{"id":"T6","span":{"begin":1397,"end":1409},"obj":"CI"},{"id":"T7","span":{"begin":1451,"end":1463},"obj":"CI"},{"id":"T8","span":{"begin":1695,"end":1707},"obj":"CI"},{"id":"T9","span":{"begin":1350,"end":1357},"obj":"CI"},{"id":"T10","span":{"begin":895,"end":902},"obj":"CI"},{"id":"T11","span":{"begin":509,"end":512},"obj":"DP"},{"id":"T12","span":{"begin":592,"end":595},"obj":"DP"},{"id":"T13","span":{"begin":482,"end":507},"obj":"DP"},{"id":"T14","span":{"begin":186,"end":211},"obj":"DP"}],"text":"A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.\nBACKGROUND: Escalating doses of selective serotonin reuptake inhibitors are often used to treat patients with a suboptimal response to the standard dose. This study assessed the efficacy and safety of dose escalation of escitalopram, up to 30 mg, in non-remitters with major depressive disorder (MDD) after treatment with the standard dose.\nMETHOD: We recruited 98 patients with MDD (aged 18-65 years). After 4 weeks of open-label treatment with 10-20 mg of escitalopram per day, non-remitters [Montgomery-Åsberg Depression Rating Scale (MADRS) score \u003e 10] were randomized 1:1 for double-blind treatment with either escitalopram (30 mg per day) or escitalopram (20 mg per day) plus placebo for 6 weeks. The primary efficacy outcome was a change in the total MADRS score.\nRESULTS: After 4 weeks of open-label treatment, 12 patients achieved remission, and 36 dropped out, leaving 50 non-remitters, of whom 44 (88%) completed the double-blind study. The primary outcome measure, the least-squares mean (standard error) change in the total MADRS score at week 6 was significantly different (p = 0.046) between the groups [-8.0 (1.2) in the placebo dose-escalation and -11.8 (1.2) in the escitalopram dose-escalation]. The dose escalation of escitalopram was well tolerated. However, the response and remission rates and quality of life showed no significant differences.\nLIMITATIONS: Small sample size and short follow-up period CONCLUSION: This study suggests that dose escalation of escitalopram up to 30 mg per day may be beneficial for the treatment of depressive symptoms in non-remitters after standard (10-20 mg/day) treatment."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T10","span":{"begin":592,"end":595},"obj":"DP"},{"id":"T11","span":{"begin":671,"end":683},"obj":"CI"},{"id":"T12","span":{"begin":169,"end":181},"obj":"CI"},{"id":"T13","span":{"begin":433,"end":445},"obj":"CI"},{"id":"T14","span":{"begin":829,"end":841},"obj":"CI"},{"id":"T15","span":{"begin":861,"end":873},"obj":"CI"},{"id":"T16","span":{"begin":1397,"end":1409},"obj":"CI"},{"id":"T17","span":{"begin":1451,"end":1463},"obj":"CI"},{"id":"T18","span":{"begin":1695,"end":1707},"obj":"CI"},{"id":"T19","span":{"begin":1350,"end":1357},"obj":"CI"},{"id":"T20","span":{"begin":895,"end":902},"obj":"CI"},{"id":"T7","span":{"begin":186,"end":211},"obj":"DP"},{"id":"T8","span":{"begin":482,"end":507},"obj":"DP"},{"id":"T9","span":{"begin":509,"end":512},"obj":"DP"}],"text":"A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.\nBACKGROUND: Escalating doses of selective serotonin reuptake inhibitors are often used to treat patients with a suboptimal response to the standard dose. This study assessed the efficacy and safety of dose escalation of escitalopram, up to 30 mg, in non-remitters with major depressive disorder (MDD) after treatment with the standard dose.\nMETHOD: We recruited 98 patients with MDD (aged 18-65 years). After 4 weeks of open-label treatment with 10-20 mg of escitalopram per day, non-remitters [Montgomery-Åsberg Depression Rating Scale (MADRS) score \u003e 10] were randomized 1:1 for double-blind treatment with either escitalopram (30 mg per day) or escitalopram (20 mg per day) plus placebo for 6 weeks. The primary efficacy outcome was a change in the total MADRS score.\nRESULTS: After 4 weeks of open-label treatment, 12 patients achieved remission, and 36 dropped out, leaving 50 non-remitters, of whom 44 (88%) completed the double-blind study. The primary outcome measure, the least-squares mean (standard error) change in the total MADRS score at week 6 was significantly different (p = 0.046) between the groups [-8.0 (1.2) in the placebo dose-escalation and -11.8 (1.2) in the escitalopram dose-escalation]. The dose escalation of escitalopram was well tolerated. However, the response and remission rates and quality of life showed no significant differences.\nLIMITATIONS: Small sample size and short follow-up period CONCLUSION: This study suggests that dose escalation of escitalopram up to 30 mg per day may be beneficial for the treatment of depressive symptoms in non-remitters after standard (10-20 mg/day) treatment."}